Back to top

Image: Bigstock

Prothena Corporation plc

Read MoreHide Full Article

Prothena's license agreement with Roche for the development and commercialization of selected antibodies targeting alpha-synuclein is a big positive. The collaboration not only boosts Prothena’s pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. Prothena recently earned a $30 million of milestone payment from Roche. The company’s shares have outperformed the industry in the year so far. We expect investor focus to remain on further updates from its late-stage candidate, NEOD001. However, Prothena is highly dependent on its collaboration partners for the development of its candidates. The company itself does not have enough resources to independently conduct studies on its candidates.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Prothena Corporation plc (PRTA) - free report >>